Top

Published in:

Open Access 01-12-2019 | Probiotics | Review

Antibiotics, gut microbiota, and Alzheimer’s disease

Authors: Francesco Angelucci, Katerina Cechova, Jana Amlerova, Jakub Hort

Published in: Journal of Neuroinflammation | Issue 1/2019

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disease whose various pathophysiological aspects are still being investigated. Recently, it has been hypothesized that AD may be associated with a dysbiosis of microbes in the intestine. In fact, the intestinal flora is able to influence the activity of the brain and cause its dysfunctions.

Given the growing interest in this topic, the purpose of this review is to analyze the role of antibiotics in relation to the gut microbiota and AD. In the first part of the review, we briefly review the role of gut microbiota in the brain and the various theories supporting the hypothesis that dysbiosis can be associated with AD pathophysiology. In the second part, we analyze the possible role of antibiotics in these events. Antibiotics are normally used to remove or prevent bacterial colonization in the human body, without targeting specific types of bacteria. As a result, broad-spectrum antibiotics can greatly affect the composition of the gut microbiota, reduce its biodiversity, and delay colonization for a long period after administration. Thus, the action of antibiotics in AD could be wide and even opposite, depending on the type of antibiotic and on the specific role of the microbiome in AD pathogenesis.

Alteration of the gut microbiota can induce changes in brain activity, which raise the possibility of therapeutic manipulation of the microbiome in AD and other neurological disorders. This field of research is currently undergoing great development, but therapeutic applications are still far away. Whether a therapeutic manipulation of gut microbiota in AD could be achieved using antibiotics is still not known. The future of antibiotics in AD depends on the research progresses in the role of gut bacteria. We must first understand how and when gut bacteria act to promote AD. Once the role of gut microbiota in AD is well established, one can think to induce modifications of the gut microbiota with the use of pre-, pro-, or antibiotics to produce therapeutic effects.

Viña J, Sanz-Ros J. Alzheimer’s disease: only prevention makes sense. Eur J Clin Invest. 2018;48(10):e13005.PubMedCrossRef

Jagust W. Imaging the evolution and pathophysiology of Alzheimer disease. Nat Rev Neurosci. 2018;19:687–700 Available from: https://doi.org/10.1038/s41583-018-0067-3.PubMedCrossRefPubMedCentral

Xin SH, Tan L, Cao X, Yu JT, Tan L. Clearance of amyloid beta and tau in Alzheimer’s disease: from mechanisms to therapy. Neurotox. Res. 2018;34(3):733–48.PubMedCrossRef

Jiang C, Li G, Huang P, Liu Z, Zhao B. The gut microbiota and Alzheimer’s disease. J Alzheimer’s Dis. 2017;58:1–15 Available from: https://doi.org/10.3233/jad-161141.CrossRef

Gareau MG. Microbiota-gut-brain axis and cognitive function. Adv Exp Med Biol. 2014:357–71 Available from: https://doi.org/10.1007/978-1-4939-0897-4_16.

Quigley EMM. Microbiota-brain-gut axis and neurodegenerative diseases. Curr Neurol Neurosci Rep. 2017;17 Available from: https://doi.org/10.1007/s11910-017-0802-6.

Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease: current evidence and future directions. Alzheimer’s Dement. 2016;12:719–32 Available from: https://doi.org/10.1016/j.jalz.2016.02.010.CrossRef

Mukherjee S, Joardar N, Sengupta S, Sinha Babu SP. Gut microbes as future therapeutics in treating inflammatory and infectious diseases: lessons from recent findings. J Nutr Biochem. 2018;61:111–28 Available from: https://doi.org/10.1016/j.jnutbio.2018.07.010.PubMedCrossRefPubMedCentral

Daliri EB-M, Tango CN, Lee BH, Oh D-H. Human microbiome restoration and safety. Int J Med Microbiol. 2018;308:487–97 Available from: https://doi.org/10.1016/j.ijmm.2018.05.002.PubMedCrossRef

10.

Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 2012;10:735–42 Available from: https://doi.org/10.1038/nrmicro2876.PubMedCrossRef

11.

Wekerle H. The gut–brain connection: triggering of brain autoimmune disease by commensal gut bacteria. Rheumatology. 2016;55:ii68–75 Available from: https://doi.org/10.1093/rheumatology/kew353.PubMedCrossRef

12.

Briguglio M, Dell’Osso B, Panzica G, Malgaroli A, Banfi G, Zanaboni Dina C, et al. Dietary neurotransmitters: a narrative review on current knowledge. Nutrients. 2018;10:591 Available from: https://doi.org/10.3390/nu10050591.PubMedCentralCrossRef

13.

Dinan TG, Cryan JF. The microbiome-gut-brain axis in health and disease. Gastroenterol Clin North Am. 2017;46:77–89 Available from: https://doi.org/10.1016/j.gtc.2016.09.007.PubMedCrossRef

14.

Bonaz B, Bazin T, Pellissier S. The vagus nerve at the interface of the microbiota-gut-brain axis. Front Neurosci. 2018;12:49.PubMedPubMedCentralCrossRef

15.

Wang HX, Wang YP. Gut microbiota-brain axis. Chin Med J (Engl). 2016.

16.

Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203–9.PubMedPubMedCentral

17.

Logsdon AF, Erickson MA, Rhea EM, Salameh TS, Banks WA. Gut reactions: how the blood–brain barrier connects the microbiome and the brain. Exp Biol Med. 2017;243:159–65 Available from: https://doi.org/10.1177/1535370217743766.CrossRef

18.

Zac-Varghese S, Tan T, Bloom SR. Hormonal interactions between gut and brain. Discov Med. 2010;10(55):543–52.PubMed

19.

Borre YE, Moloney RD, Clarke G, Dinan TG, Cryan JF. The impact of microbiota on brain and behavior: mechanisms & therapeutic potential. Adv Exp Med Biol. 2014;817:373–403.PubMedCrossRef

20.

Links between gut microbes and depression strengthened. Nature. 2019;566(7742):7.

21.

Galland L. The gut microbiome and the brain. J Med Food. 2014;17:1261–72 Available from: https://doi.org/10.1089/jmf.2014.7000.PubMedPubMedCentralCrossRef

22.

Alam R, Abdolmaleky HM, Zhou J-R. Microbiome, inflammation, epigenetic alterations, and mental diseases. Am J Med Genet Part B Neuropsychiatr Genet. 2017;174:651–60 Available from: https://doi.org/10.1002/ajmg.b.32567.CrossRef

23.

Johnson KV-A, Foster KR. Why does the microbiome affect behaviour? Nat Rev Microbiol. 2018;16:647–55 Available from: https://doi.org/10.1038/s41579-018-0014-3.PubMedCrossRef

24.

Gareau MG, Wine E, Rodrigues DM, Cho JH, Whary MT, Philpott DJ, et al. Bacterial infection causes stress-induced memory dysfunction in mice. Gut. 2010;60:307–17 Available from: https://doi.org/10.1136/gut.2009.202515.PubMedCrossRef

25.

Cox LM, Weiner HL. Microbiota signaling pathways that influence neurologic disease. Neurotherapeutics. 2018;15:135–45 Available from: https://doi.org/10.1007/s13311-017-0598-8.PubMedPubMedCentralCrossRef

26.

Lach G, Schellekens H, Dinan TG, Cryan JF. Anxiety, depression, and the microbiome: a role for gut peptides. Neurotherapeutics. 2017;15:36–59 Available from: https://doi.org/10.1007/s13311-017-0585-0.PubMedCentralCrossRef

27.

Braakman HMH, van Ingen J. Can epilepsy be treated by antibiotics? J Neurol. 2018;265:1934–6 Available from: https://doi.org/10.1007/s00415-018-8943-3.PubMedCrossRef

28.

Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, et al. Unraveling gut microbiota in Parkinson’s disease and atypical parkinsonism. Mov Disord. 2018;34:396–405 Available from: https://doi.org/10.1002/mds.27581.PubMedCrossRef

29.

Kong G, Cao K-AL, Judd LM, Li S, Renoir T, Hannan AJ. Microbiome profiling reveals gut dysbiosis in a transgenic mouse model of Huntington’s disease. Neurobiol Dis. 2018; Available from: https://doi.org/10.1016/j.nbd.2018.09.001.

30.

Kirby T, Ochoa-Repáraz J. The gut microbiome in multiple sclerosis: a potential therapeutic avenue. Med Sci. 2018;6:69 Available from: https://doi.org/10.3390/medsci6030069.

31.

DiSabato DJ, Quan N, Godbout JP. Neuroinflammation: the devil is in the details. J Neurochem. 2016;139:136–53 Available from: https://doi.org/10.1111/jnc.13607.PubMedPubMedCentralCrossRef

32.

Minter MR, Taylor JM, Crack PJ. The contribution of neuroinflammation to amyloid toxicity in Alzheimer’s disease. J Neurochem. 2015;136:457–74 Available from: https://doi.org/10.1111/jnc.13411.PubMedCrossRef

33.

Bagyinszky E, Van GV, Shim K, Suk K, An SSA, Kim S. Role of inflammatory molecules in the Alzheimer’s disease progression and diagnosis. J Neurol Sci. 2017;376:242–54 Available from: https://doi.org/10.1016/j.jns.2017.03.031.PubMedCrossRef

34.

Wang M-M, Miao D, Cao X-P, Tan L, Tan L. Innate immune activation in Alzheimer’s disease. Ann Transl Med. 2018;6:177 Available from: https://doi.org/10.21037/atm.2018.04.20.PubMedPubMedCentralCrossRef

35.

Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016.

36.

Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS One. 2010;5(11):e13950.PubMedPubMedCentralCrossRef

37.

Fan Z, Brooks DJ, Okello A, Edison P. An early and late peak in microglial activation in Alzheimer’s disease trajectory. Brain. 2017;140(3):792–803.PubMedPubMedCentral

38.

Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet. 2009;41(10):1094–9.PubMedCrossRef

39.

Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, et al. Genome-wide association analysis reveals putative Alzheimer’s disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008;83(5):623–32.PubMedPubMedCentralCrossRef

40.

Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell. 2015;160(6):1061–71.PubMedPubMedCentralCrossRef

41.

Crehan H, Hardy J, Pocock J. Blockage of CR1 prevents activation of rodent microglia. Neurobiol Dis. 2013;54:139–49.PubMedCrossRef

42.

Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, et al. Alzheimer’s disease risk gene cd33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78(4):631–43.PubMedPubMedCentralCrossRef

43.

Clark IA, Vissel B. Amyloid β: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer’s disease. Br J Pharmacol. 2015;172:3714–27 Available from: https://doi.org/10.1111/bph.13181.PubMedPubMedCentralCrossRef

44.

Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, et al. The Alzheimer’s disease-associated amyloid β-protein is an antimicrobial peptide. PLoS One. 2010;5:e9505 Available from: https://doi.org/10.1371/journal.pone.0009505.PubMedPubMedCentralCrossRef

45.

Games D, Adams D, Alessandrini R, Barbour R, Borthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 1995;373(6514):523–7.PubMedCrossRef

46.

Cai Z, Hussain MD, Yan LJ. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer’s disease. Int J Neurosci. 2014;124(5):307–21.PubMedCrossRef

47.

Dong Y, Li X, Cheng JHL. Drug development for Alzheimer’s disease: microglia induced neuroinflammation as a target? Int J Mol Sci. 2019;20.PubMedCentralCrossRef

48.

Pretorius E, Bester J, Kell DB. A bacterial component to Alzheimer’s-type dementia seen via a systems biology approach that links iron dysregulation and inflammagen shedding to disease. J Alzheimers Dis. 2016;53:1237–56 Available from: https://doi.org/10.3233/jad-160318.PubMedPubMedCentralCrossRef

49.

Hu X, Wang T, Jin F. Alzheimer’s disease and gut microbiota. Sci China Life Sci [Internet]. Springer Nature. 2016;59:1006–23 Available from: https://doi.org/10.1007/s11427-016-5083-9.CrossRef

50.

Ashraf GM, Tarasov VV, Makhmutovа A, Chubarev VN, Avila-Rodriguez M, Bachurin SO, et al. The possibility of an infectious etiology of Alzheimer disease. Mol Neurobiol. 2018; Available from: https://doi.org/10.1007/s12035-018-1388-y.PubMedCrossRef

51.

Moir RD, Lathe R, Tanzi RE. The antimicrobial protection hypothesis of Alzheimer’s disease. Alzheimers Dement. 2018;14:1602–14 Available from: https://doi.org/10.1016/j.jalz.2018.06.3040.PubMedCrossRef

52.

Michaud M, Balardy L, Moulis G, Gaudin C, Peyrot C, Vellas B, et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc. 2013;14:877–82 Available from: https://doi.org/10.1016/j.jamda.2013.05.009.PubMedCrossRef

53.

Harach T, Marungruang N, Duthilleul N, Cheatham V, Mc Coy KD, Frisoni G, et al. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci Rep. 2017;7 Available from: https://doi.org/10.1038/srep41802.

54.

Roubaud-Baudron C, Quadrio I, Krolak-Salmon P, Mégraud F, Salles N. Impact of chronic Helicobacter pylori infection on Alzheimer’s disease: preliminary results. Neurobiol Aging. 2011.

55.

Bu XL, Yao XQ, Jiao SS, Zeng F, Liu YH, Xiang Y, et al. A study on the association between infectious burden and Alzheimer’s disease. Eur J Neurol. 2015;22(12):1519–25.PubMedCrossRef

56.

Wang XL, Zeng J, Yang Y, Xiong Y, Zhang ZH, Qiu M, et al. Helicobacter pylori filtrate induces Alzheimer-like tau hyperphosphorylation by activating glycogen synthase kinase-3β. J Alzheimers Dis. 2015;43:153–65.CrossRef

57.

Pisa Di AR, Fernández-Fernández AM, Rábano A, Carrasco L. Polymicrobial infections in brain tissue from Alzheimer’s disease patients. Sci Rep. 2017;7(1):5559.CrossRef

58.

Zhao Y, Jaber VLW. Secretory products of the human GI tract microbiome and their potential impact on Alzheimer’s disease (AD): detection of lipopolysaccharide (LPS) in AD hippocampus. Front Cell Infect Microbiol. 2017;7:318.PubMedPubMedCentralCrossRef

59.

Cattaneo A, Cattane N, Galluzzi S, Provasi S, Lopizzo N, Festari C, et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging. 2017;49:60–8.PubMedCrossRef

60.

Itzhaki RF. Herpes simplex virus type 1 and Alzheimer’s disease: possible mechanisms and signposts. FASEB J. 2017;31(8):3216–26.PubMedCrossRef

61.

Barnes LL, Capuano AW, Aiello AE, Turner AD, Yolken RH, Torrey EF, et al. Cytomegalovirus infection and risk of Alzheimer disease in older black and white individuals. J Infect Dis. 2015;211(2):230–7.PubMedCrossRef

62.

Bernstein HG, Keilhoff G, Dobrowolny HSJ. Binding varicella zoster virus: an underestimated facet of insulin-degrading enzyme’s implication for Alzheimer’s disease pathology? Eur Arch Psychiatry Clin Neurosci. 2019.

63.

Lin WR, Casas I, Wilcock GK, Itzhaki RF. Neurotropic viruses and Alzheimer’s disease: a search for varicella zoster virus DNA by the polymerase chain reaction. J Neurol Neurosurg Psychiatry. 2008.

64.

L H, O J, W B, J A, E S, H G, et al. Interaction between Cytomegalovirus and herpes simplex virus type 1 associated with the risk of Alzheimer’s disease development. J Alzheimer’s Dis. 2018.

65.

Maqsood R, Stone TW. The gut-brain axis, BDNF, NMDA and CNS disorders. Neurochem Res. 2016;41:2819–35 Available from: https://doi.org/10.1007/s11064-016-2039-1.PubMedCrossRef

66.

Marques C, Meireles M, Faria A, Calhau C. High-fat diet–induced dysbiosis as a cause of neuroinflammation. Biol Psychiatry. 2016;80:e3–4 Available from: https://doi.org/10.1016/j.biopsych.2015.10.027.PubMedCrossRef

67.

Li H, Sun J, Du J, Wang F, Fang R, Yu C, et al. Clostridium butyricum exerts a neuroprotective effect in a mouse model of traumatic brain injury via the gut-brain axis. Neurogastroenterol Motil. 2017;30:e13260 Available from: https://doi.org/10.1111/nmo.13260.PubMedCrossRef

68.

Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7:189–200 Available from: https://doi.org/10.1080/19490976.2015.1134082.PubMedPubMedCentralCrossRef

69.

Caracciolo B, Xu W, Collins S, Fratiglioni L. Cognitive decline, dietary factors and gut–brain interactions. Mech Ageing Dev. 2014;136(137):59–69 Available from: https://doi.org/10.1016/j.mad.2013.11.011.PubMedCrossRef

70.

Claesson MJ, Jeffery IB, Conde S, Power SE, O’Connor EM, Cusack S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012;488:178–84 Available from: https://doi.org/10.1038/nature11319.PubMedCrossRef

71.

Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging: an evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2006;908:244–54 Available from: https://doi.org/10.1111/j.1749-6632.2000.tb06651.x.CrossRef

72.

Minter MR, Zhang C, Leone V, Ringus DL, Zhang X, Oyler-Castrillo P, et al. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer’s disease. Sci Rep. 2016;6 Available from: https://doi.org/10.1038/srep30028.

73.

Erny D, Hrabě de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18:965–77 Available from: https://doi.org/10.1038/nn.4030.PubMedPubMedCentralCrossRef

74.

Ege MJ. The hygiene hypothesis in the age of the microbiome. Ann Am Thorac Soc. 2017;14:S348–53 Available from: https://doi.org/10.1513/annalsats.201702-139aw.PubMedCrossRef

75.

Browne TC, McQuillan K, McManus RM, O’Reilly J-A, Mills KHG, Lynch MA. IFN-γ production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer’s disease. J Immunol. 2013;190:2241–51 Available from: https://doi.org/10.4049/jimmunol.1200947.PubMedCrossRef

76.

Pellicanò M, Larbi A, Goldeck D, Colonna-Romano G, Buffa S, Bulati M, et al. Immune profiling of Alzheimer patients. J Neuroimmunol. 2012;242:52–9 Available from: https://doi.org/10.1016/j.jneuroim.2011.11.005.PubMedCrossRef

77.

Saresella M, Calabrese E, Marventano I, Piancone F, Gatti A, Calvo MG, et al. PD1 negative and PD1 positive CD4+ T regulatory cells in mild cognitive impairment and Alzheimer’s disease. J Alzheimer’s Dis. 2010;21:927–38 Available from: https://doi.org/10.3233/jad-2010-091696.CrossRef

78.

Dansokho C, Ait Ahmed D, Aid S, Toly-Ndour C, Chaigneau T, Calle V, et al. Regulatory T cells delay disease progression in Alzheimer-like pathology. Brain. 2016;139:1237–51 Available from: https://doi.org/10.1093/brain/awv408.PubMedCrossRef

79.

Larbi A, Pawelec G, Witkowski JM, Schipper HM, Derhovanessian E, Goldeck D, et al. Dramatic shifts in circulating cd4 but not cd8 t cell subsets in mild alzheimer’s disease. J Alzheimer’s Dis. 2009;17:91–103 Available from: https://doi.org/10.3233/jad-2009-1015.CrossRef

80.

Itzhaki RF, Wozniak MA. Herpes simplex virus type 1 in Alzheimer’s disease: the enemy within. J Alzheimer’s Dis. 2008;13:393–405 Available from: https://doi.org/10.3233/jad-2008-13405.CrossRef

81.

Laitinen MH, Ngandu T, Rovio S, Helkala E-L, Uusitalo U, Viitanen M, et al. Fat intake at midlife and risk of dementia and Alzheimer’s disease: a population-based study. Dement Geriatr Cogn Disord. 2006;22:99–107 Available from: https://doi.org/10.1159/000093478.PubMedCrossRef

82.

Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut. 2016;65:1906–15 Available from: https://doi.org/10.1136/gutjnl-2016-312297.PubMedCrossRef

83.

Neuman H, Forsythe P, Uzan A, Avni O, Koren O. Antibiotics in early life: dysbiosis and the damage done. FEMS Microbiol Rev. 2018; Available from: https://doi.org/10.1093/femsre/fuy018.

84.

Fröhlich EE, Farzi A, Mayerhofer R, Reichmann F, Jačan A, Wagner B, et al. Cognitive impairment by antibiotic-induced gut dysbiosis: analysis of gut microbiota-brain communication. Brain Behav Immun. 2016;56:140–55 Available from: https://doi.org/10.1016/j.bbi.2016.02.020.PubMedPubMedCentralCrossRef

85.

Neufeld NH, Mohamed NS, Grujich N, Shulman K. Acute neuropsychiatric symptoms associated with antibiotic treatment of Helicobacter pylori infections. J Psychiatr Pract. 2017;23:25–35 Available from: https://doi.org/10.1097/pra.0000000000000205.PubMedCrossRef

86.

Zarrinpar A, Chaix A, Xu ZZ, Chang MW, Marotz CA, Saghatelian A, et al. Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism. Nat Commun. 2018;9 Available from: https://doi.org/10.1038/s41467-018-05336-9.

87.

Wang T, Hu X, Liang S, Li W, Wu X, Wang L, et al. Lactobacillus fermentum NS9 restores the antibiotic induced physiological and psychological abnormalities in rats. Benef Microbes. 2015;6:707–17 Available from: https://doi.org/10.3920/bm2014.0177.PubMedCrossRef

88.

Neufeld KM, Kang N, Bienenstock J, Foster JA. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil. 2010;23:255–e119 Available from: https://doi.org/10.1111/j.1365-2982.2010.01620.x.PubMedCrossRef

89.

Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology. 2011;141:599–609.e3 Available from: https://doi.org/10.1053/j.gastro.2011.04.052.PubMedCrossRef

90.

Ravelli KG, Rosário B dos A, Camarini R, Hernandes MS, Britto LR. Intracerebroventricular streptozotocin as a model of Alzheimer’s disease: neurochemical and behavioral characterization in mice. Neurotox Res. 2016;31:327–33 Available from: https://doi.org/10.1007/s12640-016-9684-7.PubMedCrossRef

91.

Furman BL. Streptozotocin-induced diabetic models in mice and rats. Curr Protoc Pharmacol. 2015:5.47.1, 5.47.20 Available from: https://doi.org/10.1002/0471141755.ph0547s70.

92.

Walker J, Harrison F. Shared neuropathological characteristics of obesity, type 2 diabetes and Alzheimer’s disease: impacts on cognitive decline. Nutrients. 2015;7:7332–57 Available from: https://doi.org/10.3390/nu7095341.PubMedPubMedCentralCrossRef

93.

Davari S, Talaei SA, Alaei H, Salami M. Probiotics treatment improves diabetes-induced impairment of synaptic activity and cognitive function: behavioral and electrophysiological proofs for microbiome–gut–brain axis. Neuroscience. 2013;240:287–96 Available from: https://doi.org/10.1016/j.neuroscience.2013.02.055.PubMedCrossRef

94.

Desbonnet L, Clarke G, Shanahan F, Dinan TG, Cryan JF. Microbiota is essential for social development in the mouse. Mol Psychiatry. 2013;19:146–8 Available from: https://doi.org/10.1038/mp.2013.65.PubMedPubMedCentralCrossRef

95.

Desbonnet L, Clarke G, Traplin A, O’Sullivan O, Crispie F, Moloney RD, et al. Gut microbiota depletion from early adolescence in mice: implications for brain and behaviour. Brain Behav Immun. 2015;48:165–73 Available from: https://doi.org/10.1016/j.bbi.2015.04.004.PubMedCrossRef

96.

Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017;21 Available from: https://doi.org/10.1186/s13054-017-1856-1.

97.

Kountouras J, Boziki M, Gavalas E, Zavos C, Grigoriadis N, Deretzi G, et al. Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer’s disease. J Neurol. 2009;256:758–67 Available from: https://doi.org/10.1007/s00415-009-5011-z.PubMedCrossRef

98.

Yulug B, Hanoglu L, Ozansoy M, Isık D, Kilic U, Kilic E, et al. Therapeutic role of rifampicin in Alzheimer’s disease. Psychiatry Clin Neurosci. 2018;72:152–9 Available from: https://doi.org/10.1111/pcn.12637.PubMedCrossRef

99.

Budni J, L. Garcez M, de Medeiros J, Cassaro E, Bellettini-Santos T, Mina F, et al. The anti-inflammatory role of minocycline in Alzheimer’s disease. Curr Alzheimer Res ; 2016;13:1319–1329. Available from: https://doi.org/10.2174/1567205013666160819124206 PubMedCrossRef

100.

Wang C, Yu J-T, Miao D, Wu Z-C, Tan M-S, Tan L. Targeting the mTOR signaling network for Alzheimer’s disease therapy. Mol Neurobiol. 2013;49:120–35 Available from: https://doi.org/10.1007/s12035-013-8505-8.PubMedCrossRef

101.

Portero-Tresserra M, Martí-Nicolovius M, Tarrés-Gatius M, Candalija A, Guillazo-Blanch G, Vale-Martínez A. Intra-hippocampal d-cycloserine rescues decreased social memory, spatial learning reversal, and synaptophysin levels in aged rats. Psychopharmacology (Berl). 2018;235(5):1463–77.PubMedCrossRef

102.

Tsai GE, Falk WE, Gunther J, Coyle JT. Improved cognition in Alzheimer’s disease with short-term D-cycloserine treatment. Am J Psychiatry. 1999;156(3):467–9.PubMed

103.

Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer’s disease. J Am Geriatr Soc. 2004;52:381–7 Available from: https://doi.org/10.1111/j.1532-5415.2004.52109.x.PubMedCrossRef

104.

Molloy DW, Standish TI, Zhou Q, Guyatt G. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer’s disease: the DARAD trial. Int J Geriatr Psychiatry. 2012;28:463–70 Available from: https://doi.org/10.1002/gps.3846.PubMedCrossRef

105.

Jones R, Laake K, Øksengård AR. D-cycloserine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002; Available from: https://doi.org/10.1002/14651858.cd003153.

106.

Richardson A, Galvan V, Lin A-L, Oddo S. How longevity research can lead to therapies for Alzheimer’s disease: the rapamycin story. Exp Gerontol. 2015;68:51–8 Available from: https://doi.org/10.1016/j.exger.2014.12.002.PubMedCrossRef

107.

Pistollato F, Iglesias RC, Ruiz R, Aparicio S, Crespo J, Lopez LD, et al. Nutritional patterns associated with the maintenance of neurocognitive functions and the risk of dementia and Alzheimer’s disease: a focus on human studies. Pharmacol. Res. 2018.

108.

Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B, et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013.

109.

Akbari E, Asemi Z, Kakhaki RD, Bahmani F, Kouchaki E, Tamtaji OR, et al. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial. Front Aging Neurosci. 2016.

110.

Athari Nik Azm S, Djazayeri A, Safa M, Azami K, Ahmadvand B, Sabbaghziarani F, et al. Lactobacillus and bifidobacterium ameliorate memory and learning deficits and oxidative stress in Aβ (1-42) injected Rats. Appl Physiol Nutr Metab. 2018.

111.

Abraham D, Feher J, Scuderi GL, Szabo D, Dobolyi A, Cservenak M, et al. Exercise and probiotics attenuate the development of Alzheimer’s disease in transgenic mice: role of microbiome. Exp Gerontol. 2019.

112.

Chen D, Yang X, Yang J, Lai G, Yong T, Tang X, et al. Prebiotic effect of Fructooligosaccharides from Morinda officinalis on Alzheimer’s disease in rodent models by targeting the microbiota-gut-brain axis. Front Aging Neurosci. 2017.

113.

Gentile CL, Weir TL. The gut microbiota at the intersection of diet and human health. Science (80- ). 2018;362:776–80 Available from: https://doi.org/10.1126/science.aau5812.CrossRef

114.

Yang B-G, Hur KY, Lee M-S. Alterations in gut microbiota and immunity by dietary fat. Yonsei Med J. 2017;58:1083 Available from: https://doi.org/10.3349/ymj.2017.58.6.1083.PubMedPubMedCentralCrossRef

115.

Hillemacher T, Bachmann O, Kahl KG, Frieling H. Alcohol, microbiome, and their effect on psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2018;85:105–15 Available from: https://doi.org/10.1016/j.pnpbp.2018.04.015.PubMedCrossRef

116.

Savin Z, Kivity S, Yonath H, Yehuda S. Smoking and the intestinal microbiome. Arch Microbiol. 2018;200:677–84 Available from: https://doi.org/10.1007/s00203-018-1506-2.PubMedCrossRef

117.

Kaczmarek JL, Thompson SV, Holscher HD. Complex interactions of circadian rhythms, eating behaviors, and the gastrointestinal microbiota and their potential impact on health. Nutr Rev. 2017;75:673–82 Available from: https://doi.org/10.1093/nutrit/nux036.PubMedPubMedCentralCrossRef

Title: Antibiotics, gut microbiota, and Alzheimer’s disease
Authors: Francesco Angelucci
Katerina Cechova
Jana Amlerova
Jakub Hort
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Probiotics
Antibiotic
Alzheimer's Disease
Respiratory Microbiota
Alzheimer's Disease
Published in: Journal of Neuroinflammation / Issue 1/2019
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/s12974-019-1494-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Antibiotics, gut microbiota, and Alzheimer’s disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke

Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson’s disease

Sustained interleukin-10 delivery reduces inflammation and improves motor function after spinal cord injury

The retinal environment induces microglia-like properties in recruited myeloid cells

Dasatinib regulates LPS-induced microglial and astrocytic neuroinflammatory responses by inhibiting AKT/STAT3 signaling

Lipopolysaccharide-induced neuroinflammation induces presynaptic disruption through a direct action on brain tissue involving microglia-derived interleukin 1 beta